



New HIV prevention interventions: how to expedite development?










Challenges: Supplies

Global Context



Sub-Saharan Africa Contex

Current funding supports 3 condoms/year/man in SS Africa

Gap for SS Africa: 1.9 billion condoms/year

Cost of Filling SS Africa Cor Gap 57 million USD/year

Source: Adapted from Global HIV Prevention Working Group





Nevertheless...



 Even if condoms would be available everywhere there would still be a great need for femalecontrolled prevention technologies









New prevention technologies

- Vaccines (T-cell based vaccines might have an impact at the population le
- Female-controlled barrier methods
- Male circumcision
- HSV-2 treatment
- Microbicides
- PrEP
- Index partner treatment
- Etc.



Ч Ч







A changing landscape

- It is likely that partial efficacy for a number of these interventions is going to be demonstrated in the next 1 – 5 years
- Doing efficacy trials on prevention interventions has become exceedingly difficult already (declining incidence in study population)
- The obligation to introduce "effective" prevention tools in the trial (general?) population, will further drive up the sample size of those studies
- The world can only accommodate "so many" phase 3 prevention tr











We cannot escape making choices











There is no mechanism

to make those choices









A way forward?

 Traditional phase 1, 2,3 testing may not be possible

 A "standardized" animal model, able to assess modes of transmission and all (combinations of intervention tools may be asking too much, but certainly comparison of products within a speci category should be feasible







What we need?



- A global HIV prevention enterprise, setting crite for a systematic assessment of promising products and their subsequent clinical development and their subsequent introduction
- The field will never organize itself in such a way the funders don't force or lure it to do so (e.g. H vaccine enterprise)













